Complementary effects ofhypoglycemic drugs in the correction of preclinical metabolic disturbances in polycystic ovary syndrome


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To establish the effects of taurine and metformin as part of combined therapy on anthropometric parameters, a total body adipose tissue component, lipids, carbohydrate metabolism, menstrual function, and ultrasound parameters of the reproductive system in women with polycystic ovary syndrome (PCOS). Subjects and methods. The study included 18-45-year-old twenty-six women diagnosed with PCOS. All the patients received combined therapy with taurine and metformin for 3 months. Preoperatively and postoperatively, anthropometric examination was performed; adipose tissue content, blood pressure, and heart rate were measured; lipid levels were determined; an oral glucose tolerance test was carried out; menstrual cycle length was estimated; ultrasound monitoring of the uterus and ovaries was done. Results. Combined therapy with taurine and metformin resulted in a decrease in body mass index (p = 0.001), systolic (p = 0.022) and diastolic (p = 0.023) blood pressure, an increase in the level of high-density lipoprotein cholesterol (p = 0.018), and a more regular menstrual cycle (p = 0.010). Conclusion. Combined therapy with taurine and metform in has a positive impact on cardiovascular risk factors and improves menstrual function in women with PCOS.

全文:

受限制的访问

作者简介

Tatyana Zykova

North State Medical University, Ministry of Health of Russia; E.E. Volosevich First City Clinical Hospital

Email: 632739@mail.ru. tatyana@atnet.ru
doctor of medical science, professor, department of facultative therapy, North State Medical University, Ministry of Health of Russia; endocrinologist, Е.Е. Volosevich First City Clinical Hospital.

Lidya Uledeva

North State Medical University, Ministry of Health of Russia; E.E. Volosevich First City Clinical Hospital

Email: lidya-uledeva@yandex.ru
therapeutist, Е.Е. Volosevich First City Clinical Hospital; assistant, department of facultative therapy, North State Medical University, Ministry of Health of Russia.

参考

  1. Fauser B.C., Tarlatzis B.C., Rebar R.W., Legro R.S., Baien A.H., Lobo R. et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil. Steril. 2012; 97(1): 28-38. e25.
  2. Conway G., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Franks S., Gambineri A. et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur. J. Endocrinol. 2014; 171(4): P1-29. doi: 10.1530/EJE-14-0253.
  3. National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome. Final report. Executive summary. Bethesda, Maryland; 2012: 1-14.
  4. Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R., Welt C.K.; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013; 98(12): 4565-92.
  5. Stumvoll M., Mitrakou A., Pimenta W., Jenssen T., Yki-Järvinen H., Van Haeften T. et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 2000; 23(3): 295-301.
  6. Зыкова Т.А., Уледева Л.В. Роль таурина в коррекции метаболических дисфункций у женщин репродуктивного возраста с синдромом поликистозных яичников. Акушерство и гинекология. 2013; 11: 65-9. [Zykova T.A., Uledeva L.V. The role of taurine in the correction of metabolic dysfunction in women of reproductive age with polycystic ovary syndrome. Obstetrics and gynecology. 2013; 11: 65-9. In Russ.]
  7. Katsiki N., Hatzitolios A.I. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. Curr. Opin. Obstet. Gynecol. 2010; 22: 466-76.
  8. Fux Otta C., Wior M., Iraci G.S., Kaplan R., Torres D., Gaido M.I., Wyse E.P. Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind and placebo control trial. Gynecol. Endocrinol. 2010; 26(3): 173-8.
  9. Lord J., Thomas R., Fox B., Acharya U., Wilkin T. The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome - a randomised double-blind, placebo-controlled trial. Br. J. Obstet. Gynaecol. 2006; 113(7): 817-24.
  10. Orio F.Jr., Palomba S., Cascella T., De Simone B., Manguso F., Savastano S. et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results a 6-month study. J. Clin. Endocrinol. Metab. 2005; 90(11): 6072-6.
  11. Cheang K.I., Huszar J.M., Best A.M. Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. Diabet. Vasc. Dis. Res. 2009; 6(2): 110-9.
  12. American College of Obstetricians and Gynecologists. Polycystic ovary syndrome. ACOG practice bulletin. Washington, DC: American College of Obstetricians and Gynecologists; 2009. 108 p.
  13. Leeman L., Acharya U. The use metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence. J. Obstet. Gynecol. 2009; 29(6): 467-72.
  14. Vause T.D., Cheung A.P., Sierra S., Claman P., Graham J., Guillemin J.A. et al.; Society of Obstetricians and Gynecologists of Canada. Ovulation induction in polycystic ovary syndrome. J. Obstet. Gynaecol. Can. 2010; 32(5): 495-502.
  15. Tomova A., Deepinder F., Robeva R., Kirilov G., Mechandjiev Z., Kumanov P. Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. Horm. Metab. Res. 2011; 43(10): 723-7.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2014
##common.cookie##